We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
Read MoreHide Full Article
Key Takeaways
Galafold raked in $371.5M in the first nine months of 2025, accounting for over 80% of FOLD's product sales.
Galafold benefits from broad global approvals and U.S. patent protection extending through 2038.
FOLD's Pombiliti Opfolda delivered $77.5M sales in the first nine months of 2025, up 61% Y/Y.
Amicus Therapeutics (FOLD - Free Report) has made solid progress with its lead marketed product, Galafold (migalastat), which generates the majority of the company’s revenues.
Galafold is approved for treating Fabry disease in patients who have amenable genetic variants. The drug is approved in several countries across the world, including the United States, the European Union, the United Kingdom and Japan. Galafold has been a key top-line driver for the company in recent quarters.
In the first nine months of 2025, Galafold generated sales worth $371.5 million, which increased around 12% on a year-over-year basis. The drug contributed more than 80% of Amicus’ net product sales during the same time. As Amicus is gearing up to report its fourth-quarter results, investors will be closely watching the sales performance of Galafold.
Galafold sales are likely to have been driven by strong commercial execution in all markets as well as strong compliance. The drug also has a strong IP portfolio in the United States, providing patent protection through 2038.
Meanwhile, the recent settlement of the Galafold patent litigation with Teva Pharmaceuticals (TEVA - Free Report) marks a significant step forward in Amicus' efforts to support Galafold.
In October 2024, Amicus signed a licensing agreement with Teva, resolving the patent lawsuit that it had filed earlier. Per the settlement terms, TEVA will not be able to sell its generic version of Galafold in the United States until January 2037.
Sales are expected to grow steadily as Amicus is looking to expand its commercial footprint, driving continued momentum for Galafold.
Besides Galafold, Amicus is also making good progress with Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), a two-component therapy, which is approved for treating adults with late-onset Pompe disease.
In the first nine months of 2025, the combo drug generated sales worth $77.5 million, up around 61% on a year-over-year basis. The approval of Pombiliti + Opfolda helped FOLD tap into a market with a significant commercial opportunity. Incremental contributions from Pombiliti + Opfolda should also aid Amicus’ top line in the fourth quarter.
Amicus is set to be acquired by BioMarin for $4.8 billion. The transaction is expected to be closed in the second quarter of 2026.
FOLD’s Competition in the Target Market
Though Amicus is riding on the success of Galafold, the company’s heavy reliance on the drug for revenues remains a concern. Rising competition in the target market also remains a headwind, as several companies currently market and sell products for treating lysosomal storage disorders, including Fabry disease.
Sanofi (SNY - Free Report) markets Fabrazyme, which is approved for treating Fabry disease. Japan-based Takeda Pharmaceuticals’ Replagal is also indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
Sanofi also markets its Pompe disease drugs, Myozyme/Lumizyme, as well as Nexviazyme. Stiff competition from established players in the target market also remains a concern for Amicus, whose resources are limited compared with a large drugmaker like SNY.
FOLD’s Price Performance, Valuation and Estimates
In the past six months, shares of Amicus have rallied 135.6% compared with the industry’s growth of 21.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, Amicus is trading at a premium to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 7.39, higher than 2.43 for the industry. The stock is trading below its five-year mean of 8.89.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share (EPS) has increased from 31 cents to 35 cents over the past 60 days. During the same time frame, EPS estimates for 2026 have declined from 70 cents to 65 cents.
Image: Bigstock
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
Key Takeaways
Amicus Therapeutics (FOLD - Free Report) has made solid progress with its lead marketed product, Galafold (migalastat), which generates the majority of the company’s revenues.
Galafold is approved for treating Fabry disease in patients who have amenable genetic variants. The drug is approved in several countries across the world, including the United States, the European Union, the United Kingdom and Japan. Galafold has been a key top-line driver for the company in recent quarters.
In the first nine months of 2025, Galafold generated sales worth $371.5 million, which increased around 12% on a year-over-year basis. The drug contributed more than 80% of Amicus’ net product sales during the same time. As Amicus is gearing up to report its fourth-quarter results, investors will be closely watching the sales performance of Galafold.
Galafold sales are likely to have been driven by strong commercial execution in all markets as well as strong compliance. The drug also has a strong IP portfolio in the United States, providing patent protection through 2038.
Meanwhile, the recent settlement of the Galafold patent litigation with Teva Pharmaceuticals (TEVA - Free Report) marks a significant step forward in Amicus' efforts to support Galafold.
In October 2024, Amicus signed a licensing agreement with Teva, resolving the patent lawsuit that it had filed earlier. Per the settlement terms, TEVA will not be able to sell its generic version of Galafold in the United States until January 2037.
Sales are expected to grow steadily as Amicus is looking to expand its commercial footprint, driving continued momentum for Galafold.
Besides Galafold, Amicus is also making good progress with Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), a two-component therapy, which is approved for treating adults with late-onset Pompe disease.
In the first nine months of 2025, the combo drug generated sales worth $77.5 million, up around 61% on a year-over-year basis. The approval of Pombiliti + Opfolda helped FOLD tap into a market with a significant commercial opportunity. Incremental contributions from Pombiliti + Opfolda should also aid Amicus’ top line in the fourth quarter.
Amicus is set to be acquired by BioMarin for $4.8 billion. The transaction is expected to be closed in the second quarter of 2026.
FOLD’s Competition in the Target Market
Though Amicus is riding on the success of Galafold, the company’s heavy reliance on the drug for revenues remains a concern. Rising competition in the target market also remains a headwind, as several companies currently market and sell products for treating lysosomal storage disorders, including Fabry disease.
Sanofi (SNY - Free Report) markets Fabrazyme, which is approved for treating Fabry disease. Japan-based Takeda Pharmaceuticals’ Replagal is also indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
Sanofi also markets its Pompe disease drugs, Myozyme/Lumizyme, as well as Nexviazyme. Stiff competition from established players in the target market also remains a concern for Amicus, whose resources are limited compared with a large drugmaker like SNY.
FOLD’s Price Performance, Valuation and Estimates
In the past six months, shares of Amicus have rallied 135.6% compared with the industry’s growth of 21.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, Amicus is trading at a premium to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 7.39, higher than 2.43 for the industry. The stock is trading below its five-year mean of 8.89.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share (EPS) has increased from 31 cents to 35 cents over the past 60 days. During the same time frame, EPS estimates for 2026 have declined from 70 cents to 65 cents.
Image Source: Zacks Investment Research
FOLD’s Zacks Rank
Amicus currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.